ПАТОГЕНЕТИЧЕСКИЕ МЕХАНИЗМЫ, ЛЕЖАЩИЕ В ОСНОВЕ РАЗВИТИЯ ОСТЕОАРТРОЗА, И СПОСОБЫ ИХ КОРРЕКЦИИ

Скачать статью в PDF
Номер журнала: 
7
Год издания: 
2016

А. Марьяновский, доктор медицинских наук, профессор РНИМУ им. Н.И. Пирогова, Москва E-mail: docaam@yandex.ru

Дегенеративно-дистрофические заболевания суставов и позвоночника занимают 1-е место по распространенности среди болезней опорнодвигательной системы. Рассмотрены подходы к патогенетической терапии остеоартроза с применением хорошо изученных препаратов, безопасность которых при длительном применении доказана.
Ключевые слова: 
травматология и ортопедия
ревматология
остеоартроз
Цель Т
Для цитирования
Марьяновский А. ПАТОГЕНЕТИЧЕСКИЕ МЕХАНИЗМЫ, ЛЕЖАЩИЕ В ОСНОВЕ РАЗВИТИЯ ОСТЕОАРТРОЗА, И СПОСОБЫ ИХ КОРРЕКЦИИ . Врач, 2016; (7): 48-51

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

Список литературы: 
  1. Lozada C., del Rio E., Reitberg D. et al. A multi-center double-blind, randomized, controlled trial (db-RCT) to evaluate the effectiveness and safety of co-administered Traumeel® (Tr14) and Zeel® (Ze14) intra-articular (IA) injections versus IA placebo in patients with moderate-to-severe pain associated with OA of the knee // Arthritis Rheumatol. – 2014; 66 (suppl.): S1266.
  2. Lesiak A., Gottwald R., Weiser M. Skutecznosc kuracji preparatem Zeel T w iniekcjach dostawowych okolostawowych i domiesniowych w chorobie zwyrodnieniowej stawow // Medycyna Biologiczna. – 2001; 2: 30–6.
  3. Gottwald R., Weiser M. Treatment of osteoarthritis of the knee with Zeel T // Medicina Biológica. – 2000; 13 (4): 109–13
  4. Wodick R., Steininger K., Zenner S. The biological treatment of articular affections – results of a study conducted with 498 patients // Biologische Medizin. – 1993; 3: 127–35.
  5. Hieber F. Intra-articular treatment of osteoarthritis and post-traumatic arthralgia with Zeel // Fortschritte der Medizin. – 1971; 89 (18): 778–80.
  6. J6. äggi R., Würgler U., Grandjean F. et al. Dual inhibition of 5-lipoxygenase/cyclooxygenase by a reconstituted homeopathic remedy; possible explanation for clinical efficacy and favourable gastrointestinal tolerability // Inflamm. Res. – 2004; 53 (4): 150–7
  7. Birnesser H., Stolt P. The homeopathic preparation Zeel comp. N: A review 7. of the molecular and clinical data // Explore (NY). – 2007; 3 (1): 16–22.
  8. Tunon H., Olavsdotter C., Bohlin L. Evaluation of anti-inflammatory activity 8. of some Swedish medicinal plants. Inhibition of prostaglandin biosynthesis and PAF-induced exocytosis // J. Ethnopharmacol. – 1995; 48: 61–76.
  9. Basini G., Santini S., Bussolati S. et al. Sanguinarine inhibits VEGF-induced 9. Akt phosphorylation // Ann. N. Y. Acad. Sci. – 2007; 1095: 371–6.
  10. Basini G., Bussolati S., Santini S. et al. Sanguinarine inhibits VEGF-induced 10. angiogenesis in a fibrin gel matrix // Biofactors. – 2007; 29 (1): 11–8.
  11. Schmolz M. Transforming Growth Factor beta (TGF-11. ): eine neue Regelstrecke für antiphlogistische Therapien? // Biol. Med. – 2000; 29 (1): 31–4.
  12. Schmolz M., Heine H. Hom12. öopathische Substanzen aus der antihomotoxischen Medizin modulieren die Synthese von TGF-1 in menschlichen Vollblutkulturen // Biol. Med. – 2001; 30 (2): 61–5.
  13. Staniková M., Bély M., Švik K. et al. Effects of Zeel comp. on experimental osteoarthritis in rabbit knee // Rheumatologia. – 1999; 13 (3): 101–8.
  14. Weh L., Fr14. öschle G. Incubation in preparations as a means of influencing cartilage mechanics: a mechanical study // Biol. Therapy. – 1990; 8 (4): 91–3.
  15. Haseeb A., Haggi T. Immunopathogenesis of osteoarthritis // Clin. 15. Immunol. – 2013; 146 (3): 185–96.
  16. Bonnet C., Walsh D. Osteoarthritis, angiogenesis and inflammation // 16. Rheumatology. – 2005; 44: 7–16.Malemud C. Anti-cytokine therapy for osteoarthritis // Drugs Aging. – 2010; 17. 27 (2): 95–115.
  17. Fernadendes J., Materl-Pelletier J., Pelletier J. The role of cytokines in 18. osteoarthritis pathophysiology // Biorheology. – 2002; 39 (1–2): 237–46.
  18. Pearle A., Scanzello C., George S. et al. Elevated high-sensitivity C-reactive 19. protein levels are associated with local inflammatory findings in patients with osteoarthritis // Osteoarthritis Cartilage. – 2007; 15 (5): 516–23.
  19. Walsh D., Pearson C. Angiogenesis in the pathogenesis of inflammatory 20. joint and lung diseases // Arthritis Res. – 2001; 3: 147–52.
  20. Mentlein R., Pufe T. New functions of angiogenic peptides in osteoarthritic 21. cartilage // Curr. Rheumatol. Rev. – 2005; 1: 37–45
  21. Vane J., Botting R. Anti-inflammatory drugs and their mechanism of action 22. // Inflamm. Res. – 1998; 47 (Suppl. 2): 78–87.
  22. Park J., Pillinger M., Abramson S. Prostaglandin E2 synthesis and 23. secretion: the role of PGE2 synthases // Clin. Immunol. – 2006; 119 (3): 229–40.
  23. Giuliano F., Warner T. Origins of prostaglandin E2: involvements of 24. cyclooxygenase (COX)-1 and COX-2 in human and rat systems // J. Pharmacol. Exp. Ther. – 2002; 303 (3): 1001–6.
  24. Kawabata A. Prostaglandin E2 and pain – an update // Biol. Pharm. Bull. – 25. 2011; 34 (8): 1170–3.
  25. Adatia A., Rainsford K., Kean W. Osteoarthritis of the knee and hip. Part I: 26. aetiology and pathogenesis as a basis for pharmacotherapy // J. Pharm. Pharmacol. – 2012; 64 (5): 617–25.
  26. Pountos I., Georgouli T., Bird H. et al. Nonsteroidal anti-inflammatory drugs: 27. prostaglandins, indications and side-effects // IJICMR. – 2011; 3: 19–27.
  27. Heller A., Koch T. et al. Lipid mediators in inflammatory disorders // 28. Drugs. – 1998; 55 (4): 487–96.
  28. Leone S., Ottani A., Bertolini A. Dual acting anti-inflammatory drugs // Curr. 29. Top Med. Chem. – 2007; 7 (3): 265–75.
  29. Espanha M. Articular cartilage: structure and histochemical composition // 30. Acta Reumatol. Port. – 2010; 35 (5): 424–33
  30. Martel-Pelletier J., Boileau C., Pelletier J. et al. Cartilage in normal and 31. osteoarthritis conditions // Best Pract. Res. Clin. Rheumatol. – 2008; 22 (2): 351–84.
  31. Aigner T., Soeder S., Haag J. IL-132. and BMPs – interactive players of cartilage matrix degradation and regeneration // Eur. Cell. Mater. – 2006; 12: 49–56.
  32. Yasuda T., Poole A. A fibronectin fragment induces type II collagen 33. degradation by collagenase through an interleukin-1-mediated pathway // Arthritis Rheum. – 2002; 46: 138–48.
  33. Lozada C., del Rio E., Reitberg D. et al. Risk-benefit of co-administerd 34. Traumeel® (Tr14) and Zeel® (Ze14) intra-articular (IA) injections in patients with moderate-to-severe pain associated with OA of the knee (OAK) // Ann. Rheum. Dis. – 2015; 74 (Suppl. 2): Abstract THU0441.